Background Serous tubal intraepithelial carcinomas (STICs) have been documented in high-grade serous ovarian carcinomas (HGSOCs). However, the rate of association between STICs and HGSOCs and, therefore, the fraction of HGSOCs that are likely to have originated from the fallopian tube (FT), has remained unclear.
Introduction
Ovarian cancer is the seventh most common cancer diagnosed in women worldwide, 1 and is responsible for over 152 000 deaths each year. 2 It has a high mortality with 80% of patients presenting at an advanced stage. 3 This can be partly attributed to the lack of effective screening strategies for ovarian cancer. Epithelial ovarian cancers are categorised into two groups. Type I tumours develop from extra-ovarian implants on the ovary that undergo malignant transformation. Type II tumours have a less clear origin and include high-grade serous ovarian carcinomas (HGSOCs). [4] [5] [6] The lack of clarity on the natural history of HGSOCs, including the difficulty in establishing its origin, has hindered the development of effective screening.
Recent evidence showed that precursor lesions arise from the secretory cell type of the fallopian tube epithelium (FTE) making it a plausible site of origin for HGSOC. 7, 8 These lesions are described as serous tubal intraepithelial carcinomas (STICs), and show stratification, loss of polarity, increased mitotic activity, marked nuclear pleomorphism, hyperchromasia, prominent nucleoli and overexpression of the tumour suppressor protein TP53 (also commonly referred to as p53). 9 The hypothesis of the tubal origin of ovarian cancer is supported by studies that have attempted to examine either: (a) the association between STICs and established HGSOCs; or (b) the presence of STICs in the fallopian tubes (FTs) of asymptomatic individuals at high risk of developing HGSOC following risk-reducing salpingo-oophorectomy (RRSO).
The rate of such associations may predict the fraction of HGSOCs that may have originated from the FT. The recognition of STIC as a potential precursor of HGSOC has important implications to change clinical practice by implementing new prevention strategies. For example, major efforts have been established in promoting opportunistic salpingectomies in patients who have completed their families and are undergoing abdominal surgeries. [10] [11] [12] In addition, risk reducing bilateral salpingectomy with preservation of the ovaries has been suggested in young women who are BRCA1/BRCA2 mutation carriers. 11 It is, therefore, important to systematically review the quality of evidence that supports the notion that the FT may act as a source of HGSOC. While systematic reviews of studies that reported the frequency of STICs in patients undergoing RRSO have been conducted, 13, 14 no such review exists for studies linking STICs to established HGSOCs. Therefore, we have systematically reviewed published studies to estimate the rate of HGSOC that is associated with STICs.
Methods

Search strategy
A systematic search of medical literature was performed by FC and AAA using: (a) Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) (1946 to Present); and (b) EMBASE , to identify studies from inception until April 2016. The search strategy can be found in supplementary data ( Figure S1 ). The search was conducted using the terms mentioned in Appendix S1. Bibliographies of the studies that met the inclusion and exclusion criteria were searched for additional relevant papers. Disputes on the inclusion of studies were discussed between FC and AAA. For studies reporting the same dataset, the study with more participants was included. The search strategy was checked further by AA and MJG.
Inclusion criteria
A study was included if it evaluated the frequency of STICs in HGSOCs and was published in an English peer-reviewed journal.
Exclusion criteria
Articles were limited to those of the English language and human participants. Meta-analyses, systematic reviews, literature reviews and case reports were not included. Molecular studies that did not report the rate of association between STICs and HGSOCs were excluded. Studies only investigating primary peritoneal and tubal high-grade serous carcinomas (HGSCs) were excluded.
Quality assessment
The 'Strengthening and Reporting of Observational Studies in Epidemiology' (STROBE) 15 checklist was used to evaluate quality in observational studies with a control group. Data extraction was conducted by FC and reviewed by AAA.
Results
One-hundred and forty-two articles were identified using our search strategy (Tables S1 and S2). After duplicates between databases were removed, 96 remained. Ninety-two studies were excluded (Table S1 ) because of either being case reports (n = 5), molecular studies (n = 34), systematic reviews (n = 3), literature reviews (n = 23), animal studies (n = 2) or conference abstracts (n = 11). Also excluded were studies with cancer cases that were not HGSOCs (n = 9) or that did not evaluate the incidence of STICs as an outcome (n = 5). A bibliography search of the remaining four articles identified a further six (Table S2 ). The characteristics of the studies and the incidence of STICs in HGSOC cases are illustrated in Table 1 . [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Coexisting STICs and pelvic serous carcinomas (including HGSOCs, tubal and peritoneal serous carcinomas) were identified at a rate ranging from 13% to 53% (mean: 37%, 95% CI: 27-48%). In cases that were identified as primary ovarian in origin, the rate of STICs was reported as 11-61% (mean: 31.3%, 95% CI: 16.5-46.1%).
Study quality
The quality assessment of the studies is illustrated in Table 2 . [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] The STROBE rating for all of the studies was 17/22 or higher. Items that were missing were relatively consistent between the studies. None of the studies explained the sample size calculation strategy, and two studies made no mention of the statistical methods used. 17, 21 Potential sources of bias were scarcely addressed: with Malmberg et al. 25 being the only study to randomise cases and controls prior to examination by a pathologist; and Tang et al. 20 being the only study to blind pathologists to the diagnosis. Studies have not adjusted for potential confounding factors that may impact on the rate of co-occurrence between STIC and HGSOC. For example, Tang et al. 20 showed that the incidence of STICs following chemotherapy is 11% compared with 29% in patients without prior chemotherapy, implying that chemotherapy could be an important confounding variable.
Other quality measures were satisfied more consistently in the majority of studies. The SEE-FIM protocol was used in all studies except one, 25 and was used only in a fraction of patients in two studies. 23, 24 An additional study conducted by Mahe et al. 26 from the same team as Tang et al. 20 investigated deeper sections of a fraction of the pelvic serous carcinoma cases. Interestingly, they identified additional STICs that were not identified from the original SEE-FIM protocol. The vast majority of studies described the classification systems that were implemented to identify HGSOCs and STICs.
Discussion
Main findings
Coexisting STICs and HGSOCs were found in 11-61% (mean: 31%, 95% CI: 17-46%). In studies with patient cohorts where known BRCA gene mutations were excluded, STICs were still identified commonly, with 33% seen by Malmberg et al. 25 and 66% by Howitt et al. 22 STICs were The wide range for the reported incidence of concurrent STICs and HGSOCs could be attributed to the variation in the methods of classifying tumours as ovarian, tubal or peritoneal, as tubal carcinomas are more likely to be associated with STICs. Inter-observer reproducibility in defining a STIC, even amongst expert pathologists, has been found to be variable. 27 The method of diagnosing STIC throughout the papers had differing combinations of morphological criteria, immunohistochemistry and sectioning protocols, contributing to the variation in the reported rate. Some studies included immunohistochemistry for p53 and Ki-67, a marker for increased cell proliferation, to confirm a STIC for cases in which diagnosis was equivocal. Studies have shown that some STICs do stain negatively for p53. [28] [29] [30] However, this could also be due to a pathological p53 deletion mutation. The difficulty in establishing p53 mutation status by immunohistochemistry highlights the need for a reliable biomarker for establishing diagnosis. The overexpression of lamininc1 has been identified in STIC cases, including those with negative p53 staining and low Ki-67 index, presenting itself as a promising biomarker. 31 There is a lack of large studies with sufficient methodological rigor using, for example, centralised pathology review. Four of the studies described case series, which has limitations in the ability to ensure that the findings are specific to the HGSOC group. Further common limitations that may account for the different reported STIC rates include retrospective data collection, small participant numbers, lack of pathologist blinding and lack of randomisation prior to examination by a pathologist.
The SEE-FIM protocol was used in the majority of studies except one, 25 and only partially in two. 23, 24 This protocol involves fixation and serial sectioning of every 2-3 mm of the tube length as well as longitudinal sectioning of the distal 2 cm of the fimbria into four pieces. This ensures a higher rate of STIC detection. However, Mahe et al. 26 identified more STICs (four out of 56 initially classed as negative) on deeper sectioning despite Tang et al. 20 implementing the SEE-FIM protocol in all 300 cases. This further highlights the difficulty in obtaining an accurate assessment of the true rate of STICs.
It is important for studies investigating the hypothesis of the tubal origin of HGSOC to exclude FT carcinoma to ensure that the STIC is not simply a manifestation of the invasive carcinoma. Some studies did not distinguish whether a FT tumour was present in HGSOC cases with STICs. 17, 23 Malmberg et al. 25 identified invasive FT carcinomas in all cases, which makes it difficult to establish a causal relationship between STICs and ovarian HGSCs. However, early HGSCs with concurrent STICs were found to always be in the FT and not the ovary. 32 This and the identification of STICs in the FTs of RRSO as well as incidental HGSC cases gives strength to the hypothesis of the origin of HGSOCs from the FT. 29 The studies rarely investigated STICs in different populations. Few studies made the differentiation between women at high and low risk of HGSOC. Factors affecting ovarian cancer risk such as nulliparity, smoking and the use of hormone replacement therapy were not delineated. Only one study investigated STIC rates based on chemotherapy status. 20 
Strengths and limitations
To our knowledge, our study is the first to conduct a systematic review of the incidence of STICs in established HGSOCs. The use of the STROBE checklist allowed the critical appraisal of the accuracy and completeness of reporting in the majority of studies. However, this checklist was developed for cohort, case-control and cross-sectional studies, and therefore was not consulted for all of the included studies. This review did not include studies investigating STICs identified in the high-risk population after RRSO as this has already been systematically reviewed. 13, 14 We did not evaluate studies that only investigated serous carcinomas of a tubal or peritoneal origin. This was to ensure a focused approach in examining the relationship between STICs and HGSOCs that appear to have originated from the ovaries. A meta-analysis was not conducted due to the methodological heterogeneity between the studies and the small sample size of individual studies. Our review may have missed studies. However, a focused aim, clear inclusion and exclusion criteria as well as the search strategy being reviewed by four authors makes this possibility unlikely.
Interpretation
After the discovery of STIC lesions in 0.4-8.5% of the asymptomatic high-risk group following RRSO, 13, 30, 33 the FTE became implicated as a potential source of pelvic serous carcinomas. STICs have also been identified in the low risk population (0.8-3.1%). 10, 30, 34 The results from this review suggest that STICs are associated with a proportion of HGSOCs. Importantly, however, a fraction of the carcinomas studied were not associated with STICs, leaving a place for alternative hypotheses for the potential site of origin. However, years of research have not identified a strong alternative hypothesis. 35 The fraction of cases without an identifiable STIC does not exclude its presence during the lifespan of the disease. The aggressive and rapidly growing nature of the malignancy has contributed to the difficulty in identifying the origin.
At the genomic level, several lines of evidence exist to support the notion that the FT may be the origin of a fraction of HGSOCs. The finding of shared TP53 mutations as well as p53 overexpression in STICs and the corresponding cancer provide strong evidence of a tubal origin. In women who had undergone RRSO, STIC and invasive carcinoma exhibited similar gene copy number changes within each case. 36 Furthermore, Kuhn et al. 37 found shorter telomeres, a genetic manifestation of cancer, in STICs compared with corresponding HGSOCs, indicating STIC formation is an early event in carcinogenesis. However, such findings are linked to STICs and do not provide sufficient evidence in isolation. Therefore, studying the association between STICs and HGSOCs is important for evaluating the hypothesis of the tubal origin of ovarian HGSCs.
Our systematic review has important clinical implications. Recent findings related to the hypothesis of the FT being the origin of HGSOCs raised the possibility of implementing risk-reducing salpingectomy rather than the standard RRSO for prevention of HGSOCs. This would be highly advantageous because the preservation of the ovaries would avoid early surgical menopause and its associated health hazards. Despite the potential substantial risk reduction, the findings of this review suggest that performing prophylactic salpingectomies may not provide total protection against HGSC. This highlights the need for additional complementary strategies for effective prevention of HGSOCs. Recent work has identified promising biomarkers that may become useful in this regard.
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Conclusion
Serous tubal intraepithelial carcinomas were identified in the FTE of a fraction of women with established HGSOC; however an accurate estimate of that fraction remains to be determined. Finding the true rate of association requires further research. The review supports the hypothesis of the FT being the origin of a fraction of HGSOCs.
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